CSPG4 and obstructive sleep apnea syndrome: In this context, we tested, for the first time in OSA, a DNA plasmid-based immunization strategy using a chimeric HuDo-CSPG4 vaccine designed to elicit both humoral and cellular immune responses against CSPG4.